Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18

Brown, 2016, Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy, N. Engl. J. Med., 375, 2561, 10.1056/NEJMoa1610497

Carroll, 2008, Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells, PLoS ONE, 3, e3289, 10.1371/journal.pone.0003289

Chmielewski, 2011, IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression, Cancer Res., 71, 5697, 10.1158/0008-5472.CAN-11-0103

Chmielewski, 2014, Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma, Immunol. Rev., 257, 83, 10.1111/imr.12125

Cohen, 1995, IL-12 deaths: explanation and a puzzle, Science, 270, 908, 10.1126/science.270.5238.908a

Dinarello, 2013, Interleukin-18 and IL-18 binding protein, Front. Immunol., 4, 289, 10.3389/fimmu.2013.00289

Frigault, 2015, Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells, Cancer Immunol. Res., 3, 356, 10.1158/2326-6066.CIR-14-0186

Hege, 2017, Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer, J. Immunother. Cancer, 5, 22, 10.1186/s40425-017-0222-9

Hunder, 2008, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, N. Engl. J. Med., 358, 2698, 10.1056/NEJMoa0800251

Hung, 1998, The central role of CD4(+) T cells in the antitumor immune response, J. Exp. Med., 188, 2357, 10.1084/jem.188.12.2357

Hurton, 2016, Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells, Proc. Natl. Acad. Sci. USA, 113, E7788, 10.1073/pnas.1610544113

Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin. Cancer Res., 12, 6106, 10.1158/1078-0432.CCR-06-1183

Kochenderfer, 2009, Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor, J. Immunother., 32, 689, 10.1097/CJI.0b013e3181ac6138

Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931

Labrecque, 2001, How much TCR does a T cell need?, Immunity, 15, 71, 10.1016/S1074-7613(01)00170-4

Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J. Clin. Oncol., 24, e20, 10.1200/JCO.2006.05.9964

Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol. Ther., 17, 1453, 10.1038/mt.2009.83

Montufar-Solis, 2007, Stimulatory and costimulatory effects of IL-18 directed to different small intestinal CD43 T cell subsets, J. Leukoc. Biol., 82, 1166, 10.1189/jlb.0207108

Nakamura, 1989, Endotoxin-induced serum factor that stimulates gamma interferon production, Infect. Immun., 57, 590, 10.1128/IAI.57.2.590-595.1989

Nakamura, 1993, Purification of a factor which provides a costimulatory signal for gamma interferon production, Infect. Immun., 61, 64, 10.1128/IAI.61.1.64-70.1993

Park, 2007, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma, Mol. Ther., 15, 825, 10.1038/sj.mt.6300104

Pegram, 2012, Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, Blood, 119, 4133, 10.1182/blood-2011-12-400044

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N. Engl. J. Med., 365, 725, 10.1056/NEJMoa1103849

Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma, Nat. Med., 14, 1264, 10.1038/nm.1882

Ren, 2017, Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition, Clin. Cancer Res., 23, 2255, 10.1158/1078-0432.CCR-16-1300

Robertson, 2006, Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer, Clin. Cancer Res., 12, 4265, 10.1158/1078-0432.CCR-06-0121

Tanyi, 2017, Possible Compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells, J. Immunother., 40, 104, 10.1097/CJI.0000000000000160

Zhang, 2012, Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application, J. Immunother., 35, 430, 10.1097/CJI.0b013e31825898e8

Zhang, 2015, Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma, Clin. Cancer Res., 21, 2278, 10.1158/1078-0432.CCR-14-2085

Zhao, 2015, structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells, Cancer Cell, 28, 415, 10.1016/j.ccell.2015.09.004